Morgan Stanley Ascendis Pharma A/S Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Morgan Stanley holds 254,785 shares of ASND stock, worth $50.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

254,785

Previous 1,903,531 86.62%

Holding current value

$50.9 Million

Previous $297 Million 85.18%

% of portfolio

0.0%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$137.41 - $179.1 $227 Million - $295 Million	-1,648,746 Reduced 86.62%	254,785 $44 Million
Q1 2025 May 15, 2025	BUY	$119.49 - $168.84 $129 Million - $182 Million	1,077,770 Added 130.52%	1,903,531 $297 Million
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $62.6 Million - $75.2 Million	513,273 Added 164.25%	825,761 $114 Million
Q3 2024 May 14, 2025	BUY	$113.0 - $153.43 $16.4 Million - $22.3 Million	145,519 Added 87.15%	312,488 $46.7 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $16.4 Million - $22.3 Million	145,519 Added 87.15%	312,488 $46.7 Million
Q2 2024 May 14, 2025	SELL	$121.07 - $153.67 $79.8 Million - $101 Million	-658,792 Reduced 79.78%	166,969 $22.8 Million
Q2 2024 Oct 17, 2024	BUY	$121.07 - $153.67 $1.81 Million - $2.29 Million	14,917 Added 9.81%	166,969 $22.8 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $1.81 Million - $2.29 Million	14,917 Added 9.81%	166,969 $22.8 Million
Q1 2024 Oct 17, 2024	SELL	$123.45 - $159.4 $1.84 Million - $2.38 Million	-14,917 Reduced 8.93%	152,052 $23 Million
Q1 2024 Aug 16, 2024	BUY	$123.45 - $159.4 $3.73 Million - $4.81 Million	30,176 Added 24.76%	152,052 $23 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $3.73 Million - $4.81 Million	30,176 Added 24.76%	152,052 $23 Million
Q4 2023 Aug 16, 2024	SELL	$86.1 - $127.36 $3.88 Million - $5.74 Million	-45,093 Reduced 27.01%	121,876 $15.4 Million
Q4 2023 Feb 13, 2024	BUY	$86.1 - $127.36 $3.89 Million - $5.76 Million	45,194 Added 58.94%	121,876 $15.4 Million
Q3 2023 Nov 15, 2023	SELL	$86.5 - $103.97 $641,830 - $771,457	-7,420 Reduced 8.82%	76,682 $7.18 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $3.44 Million - $4.81 Million	-49,116 Reduced 36.87%	84,102 $7.51 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $5.27 Million - $6.37 Million	50,275 Added 60.61%	133,218 $14.3 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $8.8 Million - $11.7 Million	-88,514 Reduced 51.62%	82,943 $10.1 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $2.09 Million - $2.74 Million	-24,890 Reduced 12.68%	171,457 $17.7 Million
Q2 2022 Oct 27, 2022	BUY	$78.08 - $117.61 $7 Million - $10.5 Million	89,668 Added 84.05%	196,347 $18.3 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $7 Million - $10.5 Million	89,668 Added 84.05%	196,347 $18.3 Million
Q1 2022 Oct 27, 2022	SELL	$102.18 - $135.75 $9.16 Million - $12.2 Million	-89,668 Reduced 45.67%	106,679 $12.5 Million
Q1 2022 May 13, 2022	BUY	$102.18 - $135.75 $4.41 Million - $5.85 Million	43,112 Added 67.82%	106,679 $12.5 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $691,296 - $922,780	5,439 Added 9.36%	63,567 $8.55 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $6.55 Million - $10.3 Million	58,128 New	58,128 $9.27 Million

Others Institutions Holding ASND

# of Institutions

276

Shares Held

60M

Call Options Held

217K

Put Options Held

73.3K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.1B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account